| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Sulfabenzamide+sulfacetamide+sulfathiazole 3.7%/2.86%/3.42% vaginal cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfabenzamide (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing sulfabenzamide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Sulfabenzamide 184 mg and sulfacetamide sodium 144 mg and sulfathiazole 172 mg vaginal tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfabenzamide (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Sulfabenzamide + sulfacetamide + sulfathiazole 184mg/143.75mg/172.5mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfabenzamide (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Sulfabenzamide + sulfacetamide + sulfathiazole 3.7%ww/2.86%ww/3.42%ww cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfabenzamide (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing sulfabenzamide and sulfacetamide and sulfathiazole (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Sulfabenzamide only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing only sulfabenzamide and sulfacetamide and sulfathiazole (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Sulfabenzamide 184 mg and sulfacetamide sodium 144 mg and sulfathiazole 172 mg vaginal tablet |
Has precise active ingredient |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Sulfabenzamide 184 mg and sulfacetamide sodium 144 mg and sulfathiazole 172 mg vaginal tablet |
Has basis of strength substance (attribute) |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Sulfabenzamide 37 mg/mL and sulfacetamide sodium 28.6 mg/mL and sulfathiazole 34.2 mg/mL vaginal cream |
Has precise active ingredient |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Sulfabenzamide 37 mg/mL and sulfacetamide sodium 28.6 mg/mL and sulfathiazole 34.2 mg/mL vaginal cream |
Has basis of strength substance (attribute) |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Sulfabenzamide- and sulfacetamide- and sulfathiazole-containing product in vaginal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Sulfabenzamide and sulfacetamide and sulfathiazole only product in vaginal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]